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Abstract
Multiple interactions between parasite ligands and their receptors on the human erythrocyte are a condition of successful
Plasmodium falciparum invasion. The identification and characterization of these receptors presents a major challenge in the
effort to understand the mechanism of invasion and to develop the means to prevent it. We describe here a novel member
of the reticulocyte-binding family homolog (RH) of P. falciparum, PfRH5, and show that it binds to a previously unrecognized
receptor on the RBC. PfRH5 is expressed as a 63 kDa protein and localized at the apical end of the invasive merozoite. We
have expressed a fragment of PfRH5 which contains the RBC-binding domain and exhibits the same pattern of interactions
with the RBC as the parent protein. Attachment is inhibited if the target cells are exposed to high concentrations of trypsin,
but not to lower concentrations or to chymotrypsin or neuraminidase. We have determined the affinity, copy number and
apparent molecular mass of the receptor protein. Thus, we have shown that PfRH5 is a novel erythrocyte-binding ligand and
the identification and partial characterization of the new RBC receptor may indicate the existence of an unrecognized P.
falciparum invasion pathway
Citation: Rodriguez M, Lustigman S, Montero E, Oksov Y, Lobo CA (2008) PfRH5: A Novel Reticulocyte-Binding Family Homolog of Plasmodium falciparum that
Binds to the Erythrocyte, and an Investigation of Its Receptor. PLoS ONE 3(10): e3300. doi:10.1371/journal.pone.0003300
Editor: David M. Ojcius, University of California Merced, United States of America
Received July 21, 2008; Accepted September 8, 2008; Published October 1, 2008
Copyright:  2008 Rodriguez et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the VP fund for new initiatives, (Mohandas Narla) New York Blood Center and the National Blood Foundation.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: clobo@nybloodcenter.org
Introduction
Plasmodium falciparum infection is the most severe, and therefore
most intensively studied form of human malaria [1]. The
pathological consequences of infection derive from the parasitemia
which develops through the cyclical asexual replication of parasites
in the victim’s red blood cells (RBC). Multiple parasite ligand-
erythrocyte receptor interactions must precede a successful
Plasmodium attack on the human red cell. The main steps in the
invasion process are: (i) initial merozoite binding and reorienta-
tion, (ii) formation of a tight junction (the irreversible commitment
of the parasite to invasion), and (iii) parasite entry [2].The
parasite’s ability first to recognize and then enter RBCs is central
to infection and thus to the disease process, and consequently
molecules involved in these steps are of especial interest for the
development of malaria prophylaxis.
A combination of biochemical and biological studies, involving
enzymatic modification of the RBC surface and the use of RBC
variants, has clearly shown differences in the susceptibility of
various RBCs to malarial invasion, and has pointed to some
essential receptor-ligand interactions. The known receptors
comprise all three major glycophorins A [3], B [4] and C [5,6],
as well as unidentified species, referred to as X [4], Y [7], Z [8]
and E [9]. The reliance of the parasite on these RBC receptors
differs between both laboratory [10–13] and field strains [14–16].
The ability of P. falciparum to exploit different receptors on the
RBC for invasion represents an important mechanism that enables
the parasite to respond to RBC polymorphisms and to evade the
host immune system.
Two major malaria ligand families have been implicated in the
various receptor–ligand interactions used by Plasmodium to invade
human erythrocytes. The micronemal proteins form the ebl family
(for erythrocyte binding ligands) [17] and consist of 6 members, all
containing a conserved cysteine-rich erythrocyte-binding domain
at the N-terminal region, called the Duffy binding-like (DBL)
domains, after region II of P. vivax Duffy-binding protein, the first
functional RBC binding element to be identified [18].
A second family of erythrocyte binding proteins, the Reticulocyte
binding Homolog (PfRH family) in Plasmodium was initially found in
the rodent malaria P. yoelii (the Py235 family) [19] and was
implicated in the ability of this parasite to invade mature mouse
RBCs. Related reticulocyte binding proteins, PvRBP-1 and 2 [20]
were subsequently identified in P. vivax. Functional genomics
analysis of the P. falciparum database yielded the PfRH family,
consisting of six genes (PfRH1, PfRH2a, PfRH2b, PfRH3, PfRH4 and
PfRH5), which share homology and structural features with both the
P. yoelii and P. vivax families [8,21,22]. The PfRH1 protein of the
RH family has been shown to bind erythrocytes in a sialic-acid-
dependent manner [7]. In contrast, PfRH2b has not been
demonstrated to bind directly to red cells; however, targeted gene
disruption has shown that it is required for a sialic-acid-independent
invasion pathway [8]. Recently, Gaur et al reported the putative
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resistant receptor [23]. All PfRH proteins except PfRh3 [24] are
expressed in merozoites and are located at their apical end,
consistent with a role in ligand–receptor interactions [8].
The PfRH5 gene in P. falciparum was identified from the P.
falciparum genome sequence [21] (PlasmoDB), but the putative
protein encoded by this gene has not been analyzed, nor has its role
in parasite invasion been explored. Additionally, an earlier report
alluded to the essential role of PfRH5 in invasion, as attempts to
disrupt PfRH5 failed [21]. This lent support to the need for a
detailed functional study of this molecule. In this report, we
characterize this final member of the PfRH family. We demonstrate
that PfRH5 binds to the surface of erythrocytes; that its target is a
sialic-acid-independent receptor; that this receptor is sensitive to
high concentrations of trypsin; and that a 143-aa recombinant
fragment of PfRH5 binds to the RBC with the same specificity as
theintactprotein.Wehave furthercharacterized itsinteractionwith
the RBC in terms of the stoichiometry (number of copies per red
cell) and affinity and obtained a molecular mass for the putative
receptor. Our results thus imply the involvement of a novel RBC
receptor molecule in P. falciparum invasion, and reveal its abundance
on the membrane and its affinity for the parasite ligand.
Results
PfRH5 is a novel member of the RH family
Ligands belonging to the reticulocyte-binding protein family,
found in different Plasmodium species, are high MW proteins that
share a low level of amino acid homology and structural features,
notably a short exon 1 encoding a signal sequence, followed by a
large exon 2 encoding the bulk of the protein, and a single
predicted transmembrane domain (TMD) close to the cytoplasmic
COOH terminus (Fig. 1 A) [25]. The gene (PFD1145c) encoding
the ligand PfRH5, described in this paper, is not a typical member
of this family, being relatively small and lacking the transmem-
brane and cytoplasmic domains (Fig. 1A). The cDNA is composed
of only 1581 bp and encodes a putative polypeptide of 526 amino
acids with a calculated molecular mass of 63 kDa. CLUSTAL W
alignments of the predicted PfRH5 amino acid sequence with the
other RH members support a familial relationship, with an overall
level of similarity of 15–30% (identity plus conservative substitu-
tions) to the different RH members [http://plasmodb.org].
PfRH5 is expressed as a 63 kDa protein in the asexual
parasite
The members of the PfRH protein family have no obvious
domain structures, such as the Region II cysteine-rich domains in
the EBL family. However, the N-terminal amino acids of the
PfRH ligands are the most highly conserved in the sequences of
these proteins. Additionally, this region contains most of the
proteins’ cysteine residues, which could reflect the presence of
binding sites. Thus, we focused on the N-terminus of PfRH5 and
chose a 143-aa sequence of PfRH5 from Asn-31 to Val-174 on the
basis of a Clustal alignment of PfRH5 with the phylogenetically
close PvRBP1 [20] (,22% overall similarity, data not shown).
This region of RH5, moreover, also exhibited significant
homology with the RBC-binding domain of PfRH4 [23]. The
Figure 1. Cartoon of PfRH ligands and characterization in the parasite. A. Schematic depiction of different members of the PfRH family,
showing location of the signal peptide, region of homology among the various RH ligands and the trans-membrane region at the C-termini of the
proteins. The bar at the bottom of PfRH5 marks the region of PfRH5 that was expressed in E. coli. B. Expression of a recombinant 43-kDa protein of
PfRH5 (rRH5), chosen on the basis of homology with putative binding domains of P. vivax reticulocyte-binding protein 1 (PvRBP1) and PfRH4. Arrow
indicates rRH5 after purification on GST-agarose column. C. Western Blot and immunoprecipitation analysis of asynchronous Dd2 parasite lysates
with anti-rRH5 antibodies (IM). Pre-immune serum (PI) was used as a negative control. Arrow indicates specific 63 kDA RH5 protein seen in lysates.
doi:10.1371/journal.pone.0003300.g001
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,43 kDa in E. coli and purified to homogeneity, using glutathione-
Sepharose 4B (Fig. 1 B). Antiserum raised in rabbits against the
purified protein was used to identify native PfRH5 in asynchro-
nous parasite extracts, by immunoprecipitation and immunoblot-
ting. Fig. 1 C shows the results of these assays, in which a 63 kDa
protein is clearly seen in the 3D7 parasite extracts, the position
corresponding to the predicted molecular mass of PfRH5. The
protein does not appear to undergo processing, as no lower MW
bands are apparent on either the blot or the autoradiograph.
Similar results were obtained from parasite extracts from Dd2 and
HB3, indicating that all these strains synthesize PfRH5, with no
perceptible difference in size (data not shown).
PfRH5 is expressed in the rhoptries of merozoites
All the PfRH proteins that have been described so far have been
localized to the apical, invasive end of the merozoite. This should
be true of PfRH5 if it plays a role in parasite entry. The subcellular
localization of RH5 was determined by immunofluorescence using
anti-RH5 rabbit antibodies. Fig. 2A shows the staining pattern
obtained on late-stage schizonts demonstrating that RH5 is indeed
located at the apical end of merozoites. The punctate staining in
this region, wherein a single dot occasionally resolves into double
foci, is a hallmark of rhoptry localization. Co-staining of late stage
schizonts was then performed, using antibodies against a known
rhoptry marker, PfRhopH3 [26]. Fig. 2 B shows the results of this
dual IFA, and reveals a partial overlap of staining patterns by the
two antisera. Thus, although both RhopH3 and PfRH5 may be
present in the rhoptries, they may be located in different parts of
the rhoptry.
We confirmed this specific localization of PfRH5 in rhoptries by
immuno-electronmicroscopic analysis (IEM). The IEM was
carried out on sections of schizont-infected RBC with anti-PfRH5
antibodies. As can be seen in Fig. 2C, discrete antibody reactivity
was observed in the electron-dense organelles with the morpho-
logical characteristics of rhoptries (indicated by arrows in Fig. 2C).
Thus, like the other RH ligands, PfRH5 is localized within the
rhoptries, strongly suggesting a role in merozoite invasion.
PfRH5 binds to erythrocytes
Having established its location at the invasive apical end of the
merozoite and homology with other known RBC binding proteins,
we performed assays to determine whether native PfRH5 binds to
RBCs. The native full-length PfRH5 was isolated from [
35S]me-
thionine/cysteine-labeled culture supernatants (HB3 strain) that
contained merozoites released from infected erythrocytes in the
absence of target erythrocytes. Studies have shown that extracel-
lular merozoites release parasite proteins into the culture, and such
culture supernatants can be a source of parasite ligands that bind
erythrocytes. Thus, [
35S]methionine/cysteine-labeled spent mero-
zoite supernatants were used as the source of RBC-binding
proteins, and when the eluate was immunoprecipitated with anti-
RH5 antiserum, a dominant band at ,63 kDa was seen (Fig. 3A,
lane WT). Thus, PfRH5 appears to be an adhesin that participates
in invasion by binding to the RBC surface.
Figure 2. Apical localization of PfRH5 in the merozoite. A Mature Dd2 schizonts were labeled with rabbit anti-PfRH5 IgG and counterstained
with FITC-labeled anti-rabbit IgG (green) using immunofluorescence microscopy. B Colocalization studies: Mature Dd2 schizonts were double-labeled
with anti-PfRH5 IgG (red) and anti-RhopH3 (green) monoclonal antibody. The merged staining (yellow) by both antibodies indicates their similar
location within the parasite. C Immunoelectron microscopy confirming the localization of PfRH5 in the rhoptries within the developing merozoites in
the Dd2 schizont. Parasites were fixed with 1% paraformaldehyde and 0.1% glutaraldehyde. Staining was detected with rabbit anti-RH5 and anti-
rabbit gold (10 nm). Scale bar represents 500 nm.
doi:10.1371/journal.pone.0003300.g002
Figure 3. Erythrocyte-binding activity of native PfRH5. A
Binding of the native PfRH5 protein in the HB3 culture supernatant
incubated with untreated (WT) erythrocytes, variously enzyme-treated
erythrocytes (N: neuraminidase; HT, high trypsin; C, chymotrypsin). The
PfRH5 parasite protein was detected in the eluate fractions by
immunoprecipitation with anti-RH5 antibodies in WT, N and C lanes
but not HT. B The same eluate samples from (A) were used for the
detection of EBA-175 by immunoprecipitation. EBA-175 binds to wild
type and chymotrypsin-treated erythrocytes but not to neuraminidase
and high trypsin-treated erythrocytes C Binding of the native RH5
protein to erythrocytes treated with lower concentrations of trypsin (LT
low trypsin and MT: moderate trypsin). D The eluate samples from (C)
were used for the detection of EBA-175 by immunoprecipitation. EBA-
175 binds to untreated erythrocytes but not to low-trypsin- and
moderate-trypsin-treated erythrocytes.
doi:10.1371/journal.pone.0003300.g003
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low and moderate trypsin and chymotrypsin, but
sensitive to treatment with high trypsin
Treatment of RBCs with enzymes that selectively cleave
moieties of surface proteins, followed by an analysis of the
resulting effects on ligand binding, afforded a first indication of
molecules that could serve as receptor(s) for PfRH5 during
invasion. RBCs were treated with neuraminidase, high trypsin
concentration, and chymotrypsin, and used for EBAs with radio-
labeled HB3 parasite supernatant in several independent exper-
iments to detect the receptor recognized by native PfRH5. Fig. 3A
shows the RBC receptor profile for PfRH5. PfRH5 binding was
unaffected by neuraminidase (N) and chymotrypsin (C) (Fig. 3 a,
lanes N and C), but was eliminated by treatment with high
concentrations of trypsin (lane HT: 10 mg/ml), indicating that
adhesion is dependent on trypsin-sensitive sites on the RBC
surface. Most malaria ligand binding assays employ lower levels of
trypsin (up to 1.5 mg/ml) to denude the RBCs of tryspin-sensitive
moieties. However routine procedures in immunohematology labs,
including that of the New York Blood Center (Reid M, personal
communication), call for a more stringent treatment of the red cell
with 10 mg/ml of trypsin for the same time period of treatment, to
ensure complete elimination of all trypsin-sensitive molecules,
besides GPA and GPC. Low and moderate concentrations of
trypsin (LT, 0.5 mg/ml; MT, 1.5 mg/ml) did not impede PfRH5
binding (Fig. 3 C). In contrast, EBA-175 binding was ablated by
treatment of the RBC with trypsin at all concentrations,
confirming that the low trypsin levels sufficed to cleave
glycophorin A residues (Fig. 3 B and 3D). Thus, PfRH5 binds to
RBCs in a sialic-acid-independent fashion, similar to PfRH4 but
unlike PfRH1. However, the PfRH4 receptor exhibits sensitivity to
low trypsin and chymotrypsin, unlike that of PfRH5, and thereby
distinguishes itself from the RBC molecule recognized in our
assay. Thus, the binding profile of native RH5 to the RBC suggests
the participation of a novel red cell receptor in merozoite invasion.
rRH5 Binds erythrocytes, yielding a similar receptor
profile
To delineate the binding region on PfRH5, a 143-aa fragment
of RH5 was assayed for erythrocyte binding. This sequence was
chosen because a similar homologous region in another RH
homolog, PfRH4 was found to bind RBCs [23]. The specificity of
the interaction of rRH5 with the erythrocytes was studied in
several ways:
(i) The binding of rRH5 to wild type and various surface-
modified erythrocytes was compared with the binding of the
native PfRH5: as can be seen in Fig. 4 A the binding profile
of rRH5 simulates that of native RH5, in that it binds to a
receptor that is non-sialylated but sensitive to high
concentrations of trypsin. Low concentrations of trypsin
(0.5 mg/ml) had no inhibitory effect on the binding, while
moderate (1.5 mg/ml) trypsin concentrations visibly de-
creased the binding. Thus rRH5 appears to bind with the
same specificity as the native PfRH5, indicating that rRH5
contains an intact receptor-binding domain, as in the native
protein. This result permits the use of rRH5 in place of the
native parasite supernatant for further analysis of its
interaction with the RBC.
(ii) To establish the specificity of the binding, the capacity of
anti-RH5 antibodies to inhibit attachment of the rPfRH5 to
erythrocytes was tested. rRH5 was incubated with wild type
erythrocytes in the erythrocyte binding assay, in the presence
of different amounts of purified anti-RH5 IgG, from 0–
10 mg IgG. Fig. 4B demonstrates specific inhibition of rRH5
binding, as with increasing amounts of antibody progres-
sively lower amounts of rRH5 were detected in the binding
eluate. This confirmed the specificity of binding of rRH5 to
the RBC.
Characterization of the interaction of rRH5 and the RBC
We undertook a quantitative analysis of the interaction between
RH5 and the RBC. The affinity of the interaction of RH5 with its
receptor, and the receptor titer on the RBC may shed light on the
identity of the receptor, and could also define the role of RH5 in
the hierarchy of molecular interactions needed for successful
invasion.
A competitive binding assay was set up by mixing labeled and
unlabeled rRH5 using increasing amounts of the unlabeled ligand,
to give total concentrations of 0.1 to 400 mM with 25 ml of packed
ghosts in a total volume of 100 ml. As Fig. 5A shows, the unlabeled
protein competes against the labeled protein, with a concentration
for 50% inhibition of ca. 5610
25 M, implying a slightly smaller
affinity (ca threefold increase in Kd). Thus specificity of binding is
retained after labeling, and the affinity is almost unperturbed.
Similar experiments with rhodamine-GST did not reveal any
binding to the ghosts (data not shown).
We accordingly performed binding assays of the rhodamine-
labeled rRH5 to resealed RBC ghosts. Varying amounts of rRH5
were incubated with a fixed concentration of ghosts, and bound
polypeptide was determined by fluorimetry on the ghosts,
dissolved in SDS. The typical parabolic binding profile shown in
Fig. 5B, delivers a dissociation constant of 12 (63) mM.
From the number of ghosts in the assay mixture and the
saturation binding concentration corresponding to the best fit to
the profile (0.42 (60.06) mM) we can calculate a copy-number for
the receptors on each cell which works out to ,10
5. This value
enables us to exclude the most abundant RBC surface-exposed
proteins, band 3 (copy number 1.2610
6 per cell), and glycophorin
A( 8 610
5 copies), as well as candidates of low abundance, such as
the Kell protein (4000–18,000).
Figure 4. Erythrocyte-binding activity of rRH5. A 0.6 mmoles of
rRH5 were used in binding assays with untreated RBCs and RBCs treated
with neuraminidase- (N), low-trypsin- (LT), medium-trypsin- (MT), high-
trypsin- (HT) and chymotrypsin, followed by elution and immunopre-
cipitation with anti-RH5 antibodies. Gels containing the immuno-
precipitates were blotted and probed with anti-RH5 antibodies. B
Antibodies to rRH5 block the erythrocyte binding of the recombinant
protein. Total IgG from rabbits immunized with rRH5, blocks
erythrocyte binding of the RH5 recombinant protein. 0.6 mmoles of
rRH5 was incubated with normal erythrocytes in the presence of
purified IgG from rabbit sera at final concentrations of 0–10 mg/100 ml.
doi:10.1371/journal.pone.0003300.g004
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To identify the receptor(s) of PfRH5 on human erythrocytes, we
used gel overlay experiments in which erythrocyte ghost proteins,
separated on SDS-PAGE, were incubated with rRH5 (Fig. 6,
rRH5) or with Dd2 culture supernatant (Fig. 6, Dd2). As a control,
GST, the fusion partner pf rRH5.was included in the overlay assay
(GST). After exposure of the ghost proteins on the membrane to
these three different antigens the blot was treated with anti-RH5
(which contains antibodies to GST too) to detect specific ligand-
receptor interactions. A non-specific ,28 kDa RBC protein
(Fig. 6, marked by asterisk) was seen in all the lanes. However,
we were able to detect a specific interaction between rRH5 and a
component of apparent molecular mass of 32 kDa on the blot of
ghost proteins (indicated by arrow, lane rRH5). The same 32 kDa
band was seen in the lanes treated with native parasite supernatant
(Dd2, indicated by arrow). Thus, the 32 kDa erythrocyte protein
interacts with rRH5 as well as the native RH5 from the parasite
supernatant. Pre-immune rabbit sera did not react with any of the
proteins on the ghost overlay (PI). To determine whether any of
the glycophorins migrated at this position on the blot, parallel
strips were treated with anti-GPA/B and anti-GPC/D. The
32 kDa band does not migrate near any of the glycophorins (lanes
GPA/B and GPC/D), thus, it appears, ruling them out as PfRH5
receptors. Future work will be directed at identifying this putative
,32 kDa receptor molecule.
Anti-RH5 does Not inhibit merozoite invasion
Since RH5 appeared to play a role in invasion by binding to the
RBC, we conjectured that antisera against rRH5 might inhibit
parasite entry . Unexpectedly, however, no significant inhibitory
effect (,4.5% after subtracting the inhibition obtained with pre-
immune) was seen on merozoite invasion of untreated RBCs when
purified anti-RH5 IgG was added to the invasion assay (Table 1,
WT, WT+Ab). We next decided to assess the effects of the
antibody on invasion into enzyme-treated red cells (Table 1). Red
cells were treated with neuraminidase, trypsin and chymotrypsin
and invasion assays were performed in the presence or absence of
0.5 mg/ml purified anti-rRH5. Inhibitory effects were assayed by
comparing the extent of inhibition caused by the antibody relative
to basal invasion efficiency observed in host cells treated with the
same enzymes. Additionally, the effect of the antibodies was
compared to those engendered by the pre-immune sera. Anti-RH5
antibodies had no effect on the invasion of the parasites into
neuraminidase-treated RBCs (Table 1, N+Ab vs N+PI). In trypsin-
treated RBCs we found a small decrease in invasion efficiencies in
the presence of the anti-RH5 antibody, compared to the pre-
immune (6.6%) that was not found to be statistically significant.
No inhibitory effect was seen in chymotrypsin-treated RBCs.
Thus, anti-RH5 does not exert a significant inhibitory effect on
parasite invasion. These same antibodies, however, did inhibit the
binding of rRH5 to the RBC. Thus, it appears that although RH5
binds RBCs, the ligand-receptor complex is not accessible to the
antibody during invasion. Alternatively, since the antibody was
directed against a small portion of the full-length RH5, it may not
occlude invasion-significant epitopes. All these invasion assays
Figure 5. Characterization of binding kinetics of rRH5 and RBC. A Competition of binding to RBCs of rhodamine-labeled against unlabeled
rRH5. Binding is inhibited by unlabeled rRH5 in a dose-dependent manner. The inhibition curve derived from scans of two independent assays shows
that rRH5 competes against the binding of labeled rRH5 at an IC50 of ca. 5610
25 M. B Binding profile of rRH5 to resealed RBC ghosts. The curve is the
calculated least-squares best fit for a population of identical independent binding sites, giving Kd=1.25 (63)610
25 M, with a saturation level
(number of sites) at 0.42 mM.
doi:10.1371/journal.pone.0003300.g005
Figure 6. PfRH5 binds to a ,32 kDa protein on human
erythrocytes. Normal erythrocyte ghost cells were separated by
SDS–PAGE, and the gel was blotted and incubated with GST (the fusion
partner of rRH5) or rRH5 or native parasite culture supernatant. After
extensive washing, bound protein was detected by rabbit anti-RH5-GST
and blots were processed by enhanced chemiluminescence (ECL,
Amersham Biosciences). A specific target protein of ,32 kDA is seen in
rRH5 lane (marked with arrow) and Dd2 lanes (marked with arrow).
Asterisk denotes a non-specific protein band that appears in control
GST and other lanes. Parallel blots were probed with anti-GPA/B or anti
GPC/D antibodies to define positions of the glycophorins relative to the
32 kDA band. Pre-immune rabbit sera did not yield any reactivity (PI).
doi:10.1371/journal.pone.0003300.g006
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work will be directed at assessing inhibition in other parasite
strains.
Discussion
Erythrocyte invasion by P. falciparum merozoites is a highly
complex and incompletely understood process. A large multi-
molecular cascade of interactions between red cell receptors and
parasite ligands is hypothesized to be involved in the sequence of
steps. However, only some of these molecules are key players, such
as can allow the parasite to maintain adequate invasion potential
despite physiological changes in host RBCs or immunological
alterations in the host. This in turn will allow the persistence of
parasites in the host and ultimately increase the success of malaria
transmission. These key molecules are most likely specific parasite
adhesin molecules, involved in the recognition and binding events
at the RBC surface that lead to eventual entry. In this paper we
present one such parasite ligand, PfRH5, the smallest member of
the PfRH family, which despite lacking a transmembrane and
cytosolic region at the C-terminus, shows significant structural and
sequence homology to the RH family (Figure 1A). The overall
gene sequence homology between the different RH family
members is low, but all contain a number of conserved blocks of
amino acids which clearly identify them as members of this ligand
family. The RH family of ligands has been postulated to play a
role in determining what RBC receptors are used during invasion
[8] and thus are expected to bind to the red cell.
Surprisingly, of the four RH ligands characterized so far, only
two have been shown to directly bind to the red cell surface,
PfRH1 to a neuraminidase- and chymotrypsin-sensitive receptor
[7], and PfRH4 to a neuraminidase-resistant but trypsin- and
chymotrypsin-sensitive molecule on the RBC [23] . We have
established that the receptor(s) recognized by PfRH5 contain no
sialic acid residues and are resistant to chymotrypsin and to low
levels of trypsin (,1.5 mg/ml), but sensitive to high levels of
trypsin (10 mg/ml). Thus, our results point to the involvement of a
new type of RBC receptor. We can rule out the involvement of the
major RBC sialoglycoproteins, the glycophorins A, B and C, since
(1) they are all highly sialylated molecules and therefore
neuraminidase-sensitive, and (2) our overlay assay points to a
232 kDa RBC protein as a candidate for the interaction, with
which none of the glycophorins conforms. Two molecules that fit
the size criterion and the sialic acid-independent nature of the
receptor are the Rh blood group proteins and the unglycosylated
form of the RBC aquaporin. The copy number of the Rh blood
group proteins is known to vary substantially among individuals
ranging from 10,000 to 200,000 molecules/RBC, while the
aquaporin is found at around 150,000 molecules per RBC [27].
Further work with cells lacking these various candidate receptor
molecules in binding and invasion assays is needed for a conclusive
identification of the receptor.
Studies on the PfRH ligands have shown that different parasite
lines exhibit significant sequence variation between the same
family members, ranging from a few amino acid changes to large
deletions [24,28]. It has also been reported that some PfRH
ligands are missing in some strains [8] . These sequence variations
might represent a type of antigenic diversity and/or govern
changes in the binding properties of the protein. The latter
explanation is supported by our recent study on Brazilian field
isolates, which associates different polymorphism in the RH
ligands with changes in the invasion pathways used by the parasite
[28]. Further complexity arises from the fact that the transcription
and expression patterns of PfRH ligands vary between different
parasite lines [8,24]. These variations have implications in the way
the proteins are utilized, for changes in the expression of PfRH
ligands could lead to the recognition of different receptors on the
erythrocyte surface and therefore merozoites with different
invasion potentials. Similar sequence analyses of PfRH5 among
different laboratory and field strains of the parasite may shed light
on the utilization of this new RH family member in invasion, and
on varying patterns of RBC receptor usage.
Cowman and Crabb had earlier reported an inability to disrupt
the PfRH5 gene [21]. Thus, it appears that PfRH5 must have a
critical function in parasite survival. Our present data, based on
antibodies against RH5, show a lack of significant inhibitory effect
on parasite invasion. This was true even when the parasite
underwent invasion selection, as evidenced by invasion assays in
RBCs treated with different enzymes. Thus, it appears that the
redundancy in erythrocyte invasion ligands of Plasmodium, allied to
the large repertoire of parasite receptors belonging to the DBL and
RH families, had been exploited leading to this absence of
inhibition of invasion by anti-PfRH5. This would not, on the other
hand, explain why, by contrast with the other PfRH family
members, PfRH5 could not be disrupted.
In summary, we have identified a novel malaria red cell binding
ligand, which is expressed at the invasive apical end of the
merozoite, and which, on the basis of gene structure and amino
acid homology, belongs to the PfRH family. We propose that
PfRH5, as previously shown for its orthologs, plays an important
adhesion function by binding to a previously unrecognized type of
receptor on the RBC. Further study of this molecule across
different laboratory and field strains of P. falciparum may provide
insights into the essential features of this critical component of the
invasion cascade, and stimulate the search for a possible role in
developing new malaria vaccines.
Materials and Methods
P. falciparum parasites
P. falciparum strains 3D7, HB3, and Dd2 were obtained from the
Malaria Research and Reference Reagent Resource Center
(MR4) and were cultured in human A
+ erythrocytes [29]. The
identity of each strain has been confirmed by microsatellite
fingerprinting [30].
Table 1. Growth inhibition assay (GIA) of the anti-PfRH5 IgG
against the Dd2clone of P. falciparum.
RBC % Parasitemia % Inhibition
Untreated RBC 4.160.20 —
Untreated+Ab 3.660.20 12
Untreated+PI 3.860.60 7.5
Neuraminidase Treated 1.460.04 —
Neuraminidase Treated+Ab 1.460.04 0
Neuraminidase Treated+PI 1.660.20 215
Trypsin Treated 3.260.04 —
Trypsin Treated+Ab 2.760.10 16
Trypsin Treated+PI 2.960.40 9.4
Chymotrypsin Treated 2.260.19 —
Chymotrypsin Treated+Ab 2.160.05 4.5
Chymotrypsin Treated+PI 2.360.10 24.5
Ab: Anti-RH5, PI: pre-immune sera.
doi:10.1371/journal.pone.0003300.t001
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production of anti-RH5
The amino acid sequence of the PfRH5 protein in the 3D7
parasite clone was used to express a fragment of PfRH5,
constituting 143 aa from Asn-31 to Val-174. A 429-bp fragment
of the PfRh5 gene encoding the 143 aa was amplified by using the
following primers: primers 59-CGC GGA TCC AAA ACG AAG
AAT CAA-39 and 59-CCG CTC GAG AAA ATC CAA ATG
TCC TTC-39. The PCR product was digested with BamHI and
Xho1 (New England Biolabs, Beverly, MA) and inserted
downstream of the T7 promoter in the E. coli expression vector,
pGEX (Amersham, Pharmacia Biotech), to obtain the plasmid
pRH5-pGEX. E. coli BL21(DE3) cells (Novagen, San Diego, CA)
were transformed with pRH5-pGEX and used for the expression
of rRH5. Soluble fusion protein was purified from Escherichia coli
using standard methodologies using glutathione-Sepharose 4B and
injected into New Zealand White rabbits using 50 mg of rRH5 on
days 0, 28, 56, and 84. The rabbit sera were collected on day 98
and were used in all the following experiments.
Biosynthetic radiolabeling and immunoprecipitation
Biosynthetic radiolabeling of asynchronous intraerythrocytic
parasites with [
35S] methionine/cysteine (ICN) was performed at
100 mCi/ml during in-vitro culture. Labeled parasites were lysed on
ice for 30 min in PBS with 1% Triton6100 and standard protease
inhibitors, added with occasional vortexing. Lysates were clarified
by centrifugation. Immunoprecipitations with pre-immune or anti-
RH5 were performed as described [5].
Immunoblotting
Saponin-lysed pellets from asynchronous parasites were sepa-
rated on 10% SDS-PAGE gels under reducing conditions and
blotted onto nitrocellulose membranes. Rabbit anti-RH5 and
appropriate secondary antibody were used to detect specific
immuno-reactivity. Pre-bleeds from the same rabbits were used as
pre-immune controls.
Immunofluorescence and immuno-electronmicroscopic
localization of PfRH5
Schizont-enriched parasites were smeared on slides and stored
at 280uC. Slides were thawed, acetone-fixed, reacted with anti-
RH5 at room temperature for 1 h, and then reacted with FITC-
conjugated goat anti-rabbit antibody (1:200) at room temperature
for 30 min. The FITC-stained images were examined with a
fluorescence microscope and recorded using Adobe Photoshop.
For co-localization studies, late-stage schizonts were double-
stained with rabbit anti-PfRH5 and 1B9 (MAb anti-RhopH3)
[26], followed by rhodamine-conjugated anti-rabbit antibody
(1:200) and FITC-conjugated anti-mouse antibody (1:200). All
smears were mounted with10 mg/ml DAPI. Images were merged
using Adobe Photoshop 5.0 software.
Immunoelectron microscopy was carried out with purified P.
falciparum schizonts as described previously [31]. Briefly, mature-
stage parasitized cells were fixed with 1% paraformaldehyde and
0.1% glutaraldehyde, and reacted with rabbit anti-rPfRH5. Anti-
rabbit Ig coupled to 10 nm gold particles was used to detect
immuno-reactivity.
Erythrocyte binding assays (EBA)
Schizont stage parasites were purified by centrifugation on
40%/70%/90% Percoll/sorbitol gradients, as described.[32]. To
make culture supernatants, purified schizonts were returned to in-
vitro culture at 2.5610
7 parasites/ml with [
35S] methionine/
cysteine (ICN) and allowed to rupture overnight. Cells were
harvested by centrifugation and radio-labeled supernatants were
stored at 280uC. To perform erythrocyte binding assays (EBAs),
radio-labeled culture supernatant was rotated with the appropriate
erythrocytes at room temperature for 2 h. The erythrocytes were
then washed three times with RPMI 1640 incomplete medium,
layered on dibutylphthalate (Sigma), and centrifuged at 6,0006g
for 1 min. The supernatant and oil were removed by aspiration.
Bound parasite proteins were eluted from the erythrocytes with
1.5 M NaCl and the eluate was used for immunoprecipitation by
anti-RH5 and anti-EBA-175 antibodies.
For enzymatic treatment, erythrocytes were treated at 1610
8
cells/ml in RPMI with three different concentrations of trypsin
(Sigma): Low trypsin (LT): 0.5 mg/ml; Moderate trypsin (MT):
1.5 mg/ml trypsin and High trypsin (HT): 10 mg/ml. Cells were
also treated with 0.025 U/ml neuraminidase (Vibrio cholerae;
Roche), or 2 mg/ml chymotrypsin (Sigma) at 37uC for 1 h. Cells
treated with trypsin were then washed and treated with 0.5 mg/ml
soybean trypsin inhibitor (Sigma) for 15 min at room temperature,
as described earlier [14]. The efficacy of each enzyme treatment
was assessed in the Laboratory of Immunohematology, New York
Blood Center, by assaying for loss of RBC agglutinability, using a
panel of monoclonal antibodies against suitable antigenic
determinants on different blood group proteins.
In EBAs with rRH5, 0.6 mmoles of recombinant protein in
100 ml of PBS at pH 7.4 was incubated with 100 ml of packed
erythrocytes, wild type and enzyme treated as described above, at
37uC for 2 h. Thereafter, the EBA was followed as described
above. rRH5 was detected in the eluate by immunoprecipitation,
followed by immuno-blotting (to minimize carryover from the
IgG) with the anti-RH5 antibodies, using a kit from Genscript and
following manufacturer’s instructions.
Labeling of rRH5 for use in binding experiments and
generation of binding profiles
Recombinant RH5 protein was labeled with Rhodamine Red
(Fluo-reporter labeling kit, Molecular Probes), according to the
manufacturer’s direction. The rhodamine-red has a reactive
succinimidyl ester moiety, which reacts with the primary amines
of proteins to form a covalent conjugate. The labeled protein was
dialyzed exhaustively against PBS, pH 7.4, for 3 days, changing
the buffer several times. A calibration standard plot (which proved
linear) was generated with 1 to 60 nmoles rhodamine-labeled
rRh5, covering the concentration range of the binding assays.
rRH5 was used in binding experiments with freshly prepared
resealed red cell ghosts (to avoid fluorescence quenching by
hemoglobin). 25 ml RBC ghosts in 100 ml PBS (pH 7.4) were
incubated with different amounts of labeled rRH5 for 2 hr at RT
and washed 4 times with 5 mM Na-Phosphate buffer, 1 mm
EDTA pH 7.4 to remove unbound protein. The ghosts were then
dissolved with 0.1% SDS. The amount of rRH5 bound to RBC
ghosts was determined from the fluorescence emission intensity at
590 nm, with excitation at 570 nm, in an RF 5301 spectrofluo-
rimeter.
Competition binding assays
2 mM Rhodamine-rRh5 was incubated with 25 ml of packed
RBC ghosts in a total volume of 200 ml of PBS at pH 7 with
increasing amounts of unlabeled rRH5, to give final concentra-
tions from 0.1 to 400 mM .The mixture was incubated at RT for
2 h and the cells were washed 4 times with 5 mM Na-Phosphate
buffer, 1 mmEDTA, pH 7.4 to remove unbound protein. The
ghosts were then dissolved with 0.1% SDS and bound labeled
rRH5 was determined by spectrofluorimetry as above.
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The overlay protein-binding assay was done using rRH5 or
native parasite supernatant (overnight) and erythrocyte ghosts.
Erythrocyte ghosts were prepared by hypotonic lysis as described
before [33]. Ghost proteins (30 mg/lane, corresponding to
,5610
7 cells) were separated by 10% SDS–PAGE and trans-
ferred onto nitrocellulose. The membrane was stained with
Ponceau stain, cut into strips and blocked with 10% milk powder
in phosphate-buffered saline/0.1% Tween-20 (PBST) for 1 h.
After washing with PBST three times, 5 min per wash, the strips
were incubated overnight at 4uC with parasite culture supernatant
(Dd2) or with rRH5. The strips were washed five times (5 min
each wash) before antigen detection proceeded as outlined above
for immuno-blotting. To find the positions of the glycophorins on
the blot, strips were treated with anti-GPA/GPB (E3 from Sigma)
or anti-GPC (E5 from Sigma).
Antibody-Mediated blocking of binding of rRH5 to RBCs
IgG was purified from either pre-immune serum or anti-RH5
serum using Immuno-pure Binding/Elution Buffer System
(Protein G) from Pierce. To assay for inhibition of erythrocyte
binding of the rPfRH5 protein, 0.6 mmoles of rRH5 was incubated
with 100 ml of packed normal erythrocytes in the presence of anti-
RH5 total IgG at a final concentration ranging from 0 to10 mg/
100 ml rabbit IgG at 37uC for 1 h. Thereafter, the EBA was
followed as described above.
Invasion assays
Schizont stage parasites were purified as above, and placed into
in-vitro culture with the appropriate target erythrocytes (untreated
or treated with enzymes, as described above). Ring stage parasites
were counted following a 20-h incubation. All invasion assays were
performed in triplicate, and at least 1,000 erythrocytes were
counted per assay. IgG was purified from either pre-immune
serum or anti-RH5 serum as indicated above. After elution from
the Protein G column, IgG was dialyzed against RPMI and added
to invasion assays at a concentration of 0.5 mg/ml. Invasion in the
presence of specific RH5 antibodies was related to invasion in the
presence of nonspecific antibodies from pre-immune serum.
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